Phase 1 Alopecia Areata Trial, Recruiting NCT07205159 Sponsor: Forte Biosciences, Inc. Condition: Alopecia Areata
Back to Alopecia Areata

Phase 1 Alopecia Areata Trial, Recruiting

NCT07205159
Recruiting Phase 1 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Men between the ages of 18 and 60, or women between the ages of 18 and 75, at the time of screening
  • People who have been diagnosed with severe or very severe alopecia areata, meaning they have lost at least 50% of the hair on their scalp (including those with complete scalp hair loss, or complete loss of scalp, face, and body hair), confirmed by a standardised scoring method and photo review, with no other known cause of hair loss

Who may not be able to join:

  • People whose hair loss is caused by a different type of condition, such as traction-related hair loss, scarring, stress-related shedding, hair-pulling disorder, chemotherapy, or male/female pattern baldness
  • People who have other scalp conditions that could affect how their hair loss is assessed, such as psoriasis, skin inflammation, or a fungal scalp infection
  • People who have an active illness affecting the whole body that is causing hair loss, such as lupus, thyroid inflammation, or certain other systemic conditions (confirm with trial site)

Important: There are additional criteria not listed here that the trial site will review. Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +61 3 7050 1941

Australian sites

St Leonards, Saint Leonards, New South Wales (nsw)
Coorparoo, Coorparoo, Queensland
South Yarra, South Yarra, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Forte Biosciences, Inc.
Registry
ClinicalTrials.gov
Start date
23 October 2025
Est. completion
10 March 2027

Where this trial is recruiting

🇦🇺 Australia 🇳🇿 New Zealand

3 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs); Change from Baseline of Severity of Alopecia Tool (SALT) score at Week 16.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov